COLLCOLLEGIUM PHARMACEUTICAL, INC
Pharmaceutical Preparations
- Revenue
- $781M
- 24% YoY
- Operating margin
- 23.0%
- 14% YoY
- EBITDA
- $184M
- 5.8% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.7×
- −$123M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear523% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear8% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $277M | $464M | $567M | $631M | $781M | 24% |
| Operating income | $18M | $33M | $167M | $170M | $180M | 5.7% |
| Net income | $72M | −$25M | $48M | $69M | $63M | 8.7% |
| Operating cash flow | $104M | $124M | $275M | $205M | $329M | 61% |
| Capex | $2M | $2M | $461K | $2M | $2M | 5.3% |
| Stock-based comp | $24M | $23M | $27M | $32M | $42M | 29% |
| Buybacks | $48M | $14M | $75M | $60M | $25M | 58% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 2
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $8M | 225 | 158 |
| FY2024 | — | — | 139 | 118 |
| FY2023 | $9M | $15M | 150 | 119 |
| FY2022 | $7M | $10M | 113 | 114 |
| FY2021 | $7M | $5M | 91 | 126 |